Clinical Trials · NCT00467649
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 112
- Start date
- May 2007
- Locations
- 37 sites, United States
- Primary endpoint
- The Percentage of Patients Achieving HbA1c <=7% at Week 24 With no Gain in Body Weight From Baseline and no Incidence of Severe Hypoglycemia